Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

GenScript Biotech Global Forum, "Scripting Possibilities", Convened AI and Biopharma Leaders in San Francisco

prnewswire.com
GNS The article discusses GenScript Biotech Corporation's Global Forum, focusing on AI in biopharma. While highlighting the company's role in facilitating discussions and its vision, the sentiment is primarily informative about industry trends rather than a direct assessment of the company's stock performance. MSFT Microsoft is mentioned as its Chief Scientific Officer, Eric Horvitz, participated in a fireside chat about AI reshaping biological discovery, particularly in protein design. The mention is in the context of industry-wide discussions, not specific to Microsoft's business performance. NVDA NVIDIA is mentioned as a participant in a panel discussing AI in drug discovery. Anthony Costa from NVIDIA highlighted the importance of defining tasks and selecting appropriate AI approaches. The mention is related to industry trends and AI strategy, not a direct company-specific outlook. AMZN Amazon was mentioned as a participant in a panel discussing the shift from AI experimentation to enterprise-scale adoption in drug discovery. The mention is in the context of industry-wide discussions on AI integration, not specific to Amazon's stock performance. AZN AstraZeneca was mentioned as a panelist in a discussion about cell therapy advancements. The mention is in the context of industry trends and execution priorities in the cell therapy space, not a specific outlook for the company. LGND Legend Biotech was mentioned as a panelist in a discussion about cell therapy advancements. The mention is in the context of industry trends and execution priorities in the cell therapy space, not a specific outlook for the company.

Panel discussions brought to life important insights into how AI could change the face of biopharma drug discovery in 2026 and beyond

PISCATAWAY, N.J., Jan. 29, 2026 /PRNewswire/ -- GenScript Biotech Corporation, a global leader in life sciences R&D and manufacturing services, successfully concluded the 2026 GenScript Biotech Global Forum on January 14 in San Francisco during the annual J.P. Morgan Healthcare Conference. Held under the theme "Scripting Possibilities – The Future of Therapeutic Innovation," the Forum convened close to 1,000 international attendees. The Forum explored how artificial intelligence is reshaping discovery and what it will take to scale innovation responsibly and reliably.

"The conversations throughout the day reinforced that biotechnology is indeed at an inflection point, but they also sharpened what that means in practice," said Ray Chen, PhD, President of GenScript Life Science Group. "What emerged clearly is that speed, precision, and collaboration only create impact when they are embedded into real workflows, real laboratories, and real operating models. We're proud of the role this forum played in bringing together leaders who are not just imagining what's next but actively shaping how innovation will scale and endure. The discussions at this year's Biotech Global Forum helped set a pragmatic, forward-looking agenda for how biopharma will translate possibility into progress throughout 2026 and beyond."

Aylin Kosova Bilgin, Chief Marketing and Corporate Communications Officer of GenScript, officially opened the forum by reinforcing GenScript's Scripting Possibilities vision and the industry's shift from AI experimentation to real-world execution. She encouraged attendees to keep asking "What if?" as the catalyst for breakthroughs that can be built, scaled, and trusted.

Fireside Chat: Scripting Possibilities for AI in Healthcare and Protein Engineering

Following Ms. Bilgin's opening remarks, a fireside chat featuring Nobel Laureate David Baker, PhD, and Eric Horvitz, MD, PhD, Chief Scientific Officer of Microsoft, examined how AI is reshaping the front end of biological discovery, particularly in protein design.

Key Insights Included:

Scripting Possibilities on the Next Frontier: Cell Therapy

The Forum's cell therapy panel explored how the field is advancing beyond early approvals, with increased focus on patient experience, durability, and real-world feasibility. Panelists from DeciBio, AstraZeneca, Legend Biotech, and Stylus Medicine emphasized execution priorities (manufacturability, consistency, turnaround time, and scalable delivery) as the space evolves.

Key Insights Included:

Scripting Possibilities to Enable AI in Drug Discovery

Leaders from NVIDIA, Absci, Jefferies, and Amazon discussed the shift from AI experimentation to enterprise-scale adoption, emphasizing that value will come from embedding AI into end-to-end discovery workflows rather than isolated pilots. Anthony Costa, PhD, Director of Digital Biology at NVIDIA, noted that effective AI strategies depend on clearly defining the task at hand and selecting the appropriate approach for each stage of discovery.

Key Insights Included:

Scripting Possibilities to Secure Biotech's Future: AI, Trust & the New Global Reality

The final panel, consisting of experts from Sidley Austin, Treehill Partners, Capgemini, and Mike Walker Consulting, examined how trust, governance, and geopolitical awareness are becoming foundational to scaling AI in biopharma. Thorsten Alexander Rall of Capgemini cautioned that "proofs of concept don't scale," underscoring the need to move beyond experimentation toward enterprise-ready operating models.

Key Insights Included:

"This year's theme, Scripting Possibilities, reflected a shared recognition across the industry that AI's impact in biopharma will be defined not by ambition alone, but by how intentionally innovation is designed, tested, and scaled," said Ms. Bilgin. "I was energized by the depth and openness of the conversations, which showed a clear readiness to turn insight into execution for the scientists, innovators, and organizations advancing discovery today and in the future. For me, 'possibilities' are not abstract. They are engineered, coded, tested, and delivered by people pushing boundaries every day. These discussions captured where the industry is today and set the direction for how GenScript, together with the broader biopharma community, will support discovery, development, and impact in the years ahead."

Explore key insights from the GenScript Biotech Global Forum and watch select sessions on demand at the GenScript Biotech Global Forum page.

About GenScript Biotech Corporation

Founded in 2002 in New Jersey, GenScript Biotech Corporation accelerates innovation in biotech and healthcare by providing researchers and companies with the building blocks needed to develop groundbreaking treatments and products. Guided by its mission to Make People and Nature Healthier Through Biotechnology, GenScript supports customers across the full innovation lifecycle - from early discovery and automation-driven research to advanced biologics and manufacturing - including through its ProBio business. GenScript has a team of over 5,700 employees and has served more than 200,000 customers across over 100 countries and regions.

Learn more here: https://www.genscript.com.

Media Contact:

Kay Chuang

[email protected]

SOURCE GenScript Biotech Corp.